Systems and methods for an intranasal drug delivery system

WO2024238817A3 Publication Date: 2025-04-03FALLON JIM (DECEASED) +2
3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/029735
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-16
Publication Date
2025-04-03

AI Technical Summary

Technical Problem

Current methods for intranasal delivery of neuron-editing biologies for mental health and cognitive enhancement lack specificity, leading to unwanted side effects due to untargeted manipulation of the central nervous system, as conventional CRISPR technologies cannot differentiate between various brain areas.

Method used

Intranasal administration of neuron-editing biologies combined with brain region activators and hemodynamic vectoring to target specific brain regions, using ligand vectors and passive hemodynamic transport to deliver CRISPR molecules directly to active neurons, thereby normalizing brain activity or enhancing cognitive capacity.

Benefits of technology

This approach allows for precise targeting of specific brain regions, minimizing side effects and enhancing treatment efficacy for mental health conditions and cognitive enhancements by ensuring that neuron-editing biologies reach only the active neurons, thereby normalizing brain activity or improving cognitive functions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Various aspects of this disclosure relate to methods of treating patients that present with mental health conditions by administering AAV9 vectors that edit genomic DNA in neurons to knockout a gene. The knockout may be mediated by a nuclease, such as Cas9, and a guide RNA. The AAV9 vectors may be administered intranasally.
Need to check novelty before this filing date? Find Prior Art